Physician profile
John Khoury
NPI 1790190429
$65,833.42
in general payments reported to CMS, 2019-2025
80 companies · $7,209 in 2025
The $7,209 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $1,808 · 2021: $5,090 · 2022: $30K · 2023: $19K · 2024: $2,069 · 2025: $7,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,250 · Travel and Lodging: $521 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,515.00 |
| Food and Beverage | $10,116.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,250.00 |
| Travel and Lodging | $521.15 |
| Education | $117.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $22,321.07 | 2021-2023 | Imbruvica |
| Janssen Biotech, INC. | $10,365.26 | 2021-2025 | Tecvayli, Talvey, Imbruvica |
| Astrazeneca Pharmaceuticals LP | $4,622.06 | 2019-2025 | Lynparza, Enhertu, Calquence |
| Novartis Pharmaceuticals Corporation | $3,690.59 | 2019-2025 | |
| Pfizer INC. | $3,641.97 | 2020-2025 | |
| Karyopharm Therapeutics INC. | $3,137.66 | 2020-2024 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $1,740.63 | 2019-2025 | Alunbrig, Iclusig, Ninlaro |
| Incyte Corporation | $1,136.05 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $927.99 | 2020-2025 | Opdivo, Reblozyl, Eliquis |
| Lilly USA, LLC | $921.94 | 2020-2025 | Verzenio, Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $895.72 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Celgene Corporation | $859.47 | 2021-2025 | Reblozyl, Pomalyst |
| Bayer Healthcare Pharmaceuticals INC. | $752.29 | 2020-2025 | |
| Exelixis INC. | $744.63 | 2020-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $726.71 | 2020-2025 | Keytruda, Lynparza, Welireg |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $673.01 | 2020-2023 | Tukysa, Tivdak, Adcetris |
| Eisai INC. | $662.64 | 2020-2024 | |
| Astellas Pharma US INC | $580.64 | 2020-2025 | Xospata, Xtandi, Padcev |
| Amgen INC. | $521.17 | 2019-2023 | Nplate, Vectibix, Xgeva |
| Genzyme Corporation | $396.57 | 2019-2025 | |
| Daiichi Sankyo INC. | $384.64 | 2021-2025 | Enhertu, Datroway |
| Alexion Pharmaceuticals, INC. | $367.17 | 2020-2024 | Ultomiris |
| Abbvie INC. | $335.45 | 2022-2025 | |
| Gilead Sciences, INC. | $287.11 | 2021-2025 | Trodelvy |
| Kite Pharma, INC. | $271.72 | 2019-2025 | Yescarta |
| Genentech USA, INC. | $262.67 | 2020-2025 | Itovebi, Venclexta, Polivy |
| Array Biopharma INC | $249.06 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Adaptive Biotechnologies Corporation | $228.25 | 2023-2025 | Clonoseq |
| Bausch & Lomb Americas INC. | $210.11 | 2023-2024 | Envista Mx60 Iol, Amvisc, Sofport Ao |
| Myovant Sciences INC. | $204.91 | 2021-2022 | |
| Ge Healthcare | $189.45 | 2021-2022 | |
| Blueprint Medicines Corporation | $188.08 | 2020-2023 | Ayvakit |
| Puma Biotechnology, INC. | $169.32 | 2019-2025 | Nerlynx |
| Sobi, INC | $166.63 | 2022-2025 | |
| Emd Serono, INC. | $166.62 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.24 | 2021-2023 | Gilotrif |
| Sumitomo Pharma America, INC. | $145.09 | 2023 | Orgovyx |
| Dova Pharmaceuticals | $118.78 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $118.56 | 2021-2022 | |
| Pharmaessentia USA Corporation | $118.28 | 2022-2025 | Besremi |
| Tolmar Pharmaceuticals, INC. | $113.60 | 2020-2022 | |
| Sk Life Science, INC. | $113.40 | 2023 | Xcopri |
| Rigel Pharmaceuticals, INC. | $107.27 | 2020-2022 | |
| Global Blood Therapeutics, INC. | $103.76 | 2020-2022 | |
| Biogen, INC. | $100.82 | 2025 | Tysabri |
| Eusa Pharma (US) LLC | $95.60 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.82 | 2021 | |
| Jazz Pharmaceuticals INC. | $91.20 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $84.25 | 2022-2025 | Libtayo |
| Beigene USA, INC. | $80.64 | 2020-2025 | Brukinsa |
| Sun Pharmaceutical Industries INC. | $75.94 | 2022-2024 | |
| Stemline Therapeutics INC. | $70.65 | 2023-2024 | Orserdu |
| Tersera Therapeutics LLC | $67.00 | 2021-2023 | Xermelo |
| Secura Bio, INC. | $59.62 | 2021-2022 | |
| Taiho Oncology, INC. | $57.98 | 2022-2023 | |
| Genmab U.S., INC. | $57.82 | 2023-2024 | Epkinly |
| Deciphera Pharmaceuticals INC. | $57.31 | 2020-2025 | Qinlock, Tgct |
| Blue Earth Diagnostics | $52.02 | 2022-2023 | |
| Novocure INC. | $49.99 | 2023-2024 | Optune |
| Mirati Therapeutics, INC. | $49.49 | 2023 | Krazati |
| Morphosys, US INC. | $46.93 | 2023 | Monjuvi |
| Agios Pharmaceuticals, INC. | $45.29 | 2019-2024 | Pyrukynd |
| Immunogen, INC. | $42.99 | 2023-2024 | Elahere, Elahere |
| Epizyme, INC. | $42.77 | 2020-2022 | |
| Abiomed | $40.11 | 2024 | Impella |
| Myriad Genetic Laboratories, INC. | $37.82 | 2021 | |
| Organon LLC | $35.90 | 2022 | |
| Recordati_rare_diseases_inc. | $35.64 | 2023-2025 | Sylvant |
| Dendreon Pharmaceuticals LLC | $30.55 | 2023 | Provenge |
| Acrotech Biopharma INC. | $29.87 | 2025 | Beleodaq |
| Adc Therapeutics America, INC. | $28.26 | 2022 | |
| Syndax Pharmaceuticals, INC. | $26.91 | 2025 | |
| Aveo Pharmaceuticals, INC. | $26.18 | 2022 | |
| Amag Pharmaceuticals, INC. | $23.98 | 2020 | |
| Aurobindo Pharma USA, INC. | $18.96 | 2020 | |
| Progenics Pharmaceuticals, INC. | $18.35 | 2022 | |
| Macrogenics, INC. | $17.64 | 2022 | |
| Boston Scientific Corporation | $16.60 | 2025 | Varithena Administration Pack |
| Tolmar, INC. | $14.48 | 2023 | |
| Apellis Pharmaceuticals, INC. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$76,272.52 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Khoury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.